Drugs that contain Pitolisant Hydrochloride

1. List of Wakix drug patents

WAKIX's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8207197 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine
Mar, 2030

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354430 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Feb, 2026

(2 years from now)

US8486947 HARMONY Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
Sep, 2029

(6 years from now)

Do you want to check out WAKIX patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 14, 2024
Orphan Drug Exclusivity (ODE) Oct 13, 2027
New Indication (I) Oct 13, 2023

NCE-1 date: 2023-08-15

Market Authorisation Date: 14 August, 2019

Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating cataplexy in patients with narcolepsy

Dosage: TABLET;ORAL

More Information on Dosage

WAKIX family patents

6

United States

5

European Union

4

Japan

2

Spain

2

Austria

2

Denmark

2

RS

2

Poland

2

Germany

2

China

2

Canada

2

ME

2

Croatia

2

Korea, Republic of

2

Cyprus

2

Portugal

2

Mexico

2

Slovenia

1

Uruguay

IB

1

IB

1

Brazil

1

Ukraine

1

Morocco

1

Singapore

1

Argentina

EA

1

EA

1

Norway

1

New Zealand

1

Taiwan

1

Australia

1

South Africa

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in